PART I Overview We are a clinical stage biopharmaceutical company dedicated to bringing innovative medicines to patients with unmet medical needs in Asia. Our initial focus is to in-license assets for development and commercialization in Greater China and other Asian markets. We have assembled a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications, each with its own distinct value proposition and the potential to drive new ...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2023-03-28 | 2022-12-31 | 0001831283-23-000041 | EDGAR | 162K words |
| 2022-03-31 | 2021-12-31 | 0001831283-22-000014 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2023-11-13 | 2023-09-30 | 0001831283-23-000126 | EDGAR | 26K words |
| 2023-08-14 | 2023-06-30 | 0001831283-23-000110 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001831283-23-000081 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001831283-22-000075 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001831283-22-000061 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001831283-22-000042 | EDGAR | — |
| 2021-12-09 | 2021-09-30 | 0001193125-21-352813 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2024-02-13 | 0001831283-24-000004 | EDGAR | 2K words |
| 2023-12-26 | 0001831283-23-000145 | EDGAR | — |
| 2023-12-20 | 0001831283-23-000141 | EDGAR | — |
| 2023-12-19 | 0001831283-23-000137 | EDGAR | — |
| 2023-12-06 | 0001831283-23-000133 | EDGAR | — |
| 2023-12-01 | 0001831283-23-000129 | EDGAR | — |
| 2023-11-13 | 0001831283-23-000124 | EDGAR | — |
| 2023-10-30 | 0001831283-23-000117 | EDGAR | — |
| 2023-08-14 | 0001831283-23-000107 | EDGAR | — |
| 2023-06-23 | 0001831283-23-000092 | EDGAR | — |
50 total filings indexed. 31 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001831283 |
| Ticker | LIANY |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report